Managing moderate-to-severe psoriasis with efalizumab: Experience at a single Spanish institute

British Journal of Dermatology

Volumn 156, Issue SUPPL. 2, 2007, Pages 24-29

  Ferrandiz C ^a   Carrascosa, J M ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Efalizumab; Moderate to severe psoriasis

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN A; EFALIZUMAB; METHOTREXATE; PSORALEN; STEROID;

ADULT; ANEMIA; ARTHROPATHY; ARTICLE; BODY SURFACE; CANCER; CELLULITIS; CHILL; CLINICAL ARTICLE; DESQUAMATION; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; EPIGASTRIC PAIN; ERYTHEMA; FEMALE; FLU LIKE SYNDROME; HISPANIC; HUMAN; LEUKOCYTOSIS; LYMPHOCYTOSIS; MALE; MONOTHERAPY; MYALGIA; NAUSEA; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX SCORE; SCORING SYSTEM; SKIN INDURATION; SPAIN; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNIVERSITY HOSPITAL;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11A; BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; PSORIASIS; SPAIN; TREATMENT OUTCOME;

EID: 33947267165     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2007.07766.x     Document Type: Article

References (18)

1. Ferrandiz C, Bordas X, Garcia-Patos V et al. Prevalence of psoriasis in Spain (Epiderma Project: phase I). J Eur Acad Dermatol Venereol 2001; 15:20-3.
2. Ferrandiz C, Pujol RM, Garcia-Patos V et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002; 46:867-73.
3. Werther WA, Gonzalez TN, O'Connor SJ et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996; 157:4986-95.
4. Shear NH, Langley RG, Ho V. Efalizumab, a reversible T-cell modulator for psoriasis. J Cutan Med Surg 2006; 9 (Suppl. 1):4-9.
5. Lebwohl M, Tyring SK, Hamilton TK et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349:2004-13.
6. Gordon KB, Papp KA, Hamilton TK et al. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290:3073-80.
7. Leonardi CL, Papp KA, Gordon KB et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005; 52:425-33.
8. Menter A, Gordon KB, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141:31-38.
9. Dubertret L, Sterry W, Bos JD et al. Efalizumab for patients with moderate to severe plaque psoriasis: the international, randomized, controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial. Br J Dermatol 2006; 155:170-81.
10. Poulin Y, Papp KA, Carey W et al. A favourable benefit ?risk ratio with efalizumab: a review of the clinical evidence. J Cutan Med Surg 2006; 9 (Suppl. 1):10-17.
11. Guenther L, Langley RG, Shear NH et al. Integrating biologic agents into management of moderate-to-severe psoriasis: a Consensus of the Canadian Psoriasis Expert Panel. J Cutan Med Surg 2004; 8:321-37.
12. Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004; 151:3-17 (supplement).
13. Menter A, Leonardi CL, Sterry W et al. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006; 54:S182-8.
14. Papp K, Miller B, Gordon K et al. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006; 54:S164-70.
15. Carey W, Glazer S, Gottlieb AB et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006; 54:S171-81.
16. Hamilton TK. Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg 2005; 24:19-27.
17. Ibbotson SH, Bilsland D, Cox NH et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004; 151:283-97.
18. Raptiva® summary of product characteristics. Serono: 2005.